The brothers of men with prostate cancer face a higher disease risk because of increased diagnostic activity, and not necessarily because they carry a genetic mutation that increases risk of the disease, according to a Swedish study.
Combined with first-line chemotherapy, intravenous delivery therapy also confers a survival benefit over oral bisphosphonates. Gareth J. Morgan, MD, PhD, lead investigator of the Medical Research Council Myeloma IX study, will share additional trial results at ASH 2010.
More than 700,000 biopsies are performed in the U.S. every year, but the technology has not always kept pace with cancer diagnosis and therapy. A new technique allows rapid and easy access to the marrow space.